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Abstract
Mohs micrographic surgery (MMS) is used to obtain clear margins in skin cancer treat-
ment. MMS involves staged excisions and complete margin assessment of the specimen 
from fresh tissue frozen sectioning. It has been shown to achieve higher cure rates with 
malignancies, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), len-
tigo maligna, melanoma in situ and dermatofibrosarcoma protuberans. This technique is 
especially useful in face, feet and hand regions to avoid cosmetic deformities.
Keywords: basal cell carcinoma, squamous cell carcinoma, Mohs, skin cancer, Mohs 
surgery
1. Introduction
Mohs micrographic surgery (MMS) is a method used by physicians to obtain clear margins in 
the treatment of skin tumors. It was first described by a general surgeon, Frederick Edwards 
Mohs [1, 2]. Originally, this technique involved the application of zinc chloride paste to the 
excised tissue for overnight. The technique was later modified with the introduction of fresh 
tissue-frozen technique and the elimination of zinc chloride fixation [3].
MMS is characterized by complete evaluation of all tumor margins. It has been proven beneficial for 
various types of skin malignancies including basal cell carcinoma (BCC), squamous cell carcinoma 
(SCC), lentigo maligna (LM) and melanoma in situ (MIS). This technique is especially useful in face, 
feet and hand regions to avoid wide excision, which may not be required for tumor control [4].
2. Indications
Recurrent tumors, tumors in the “h-zone” (central face, eyelids, eyebrows, nose, lips, chin, ear, 
hand, genitalia, feet, nail units, ankles and nipples/areola), tumors with more than 2 cm diameter 
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and tumors with aggressive histopathologic findings are candidates for MMS. In 2012, appropri-
ate use criteria have been established by American Academy of Dermatology (AAD) and other 
collaborating organizations [5]. According to these criteria, all BCC, SCC, LM and MIS located in 
the “h-zone” and the “m-zone” (cheeks, forehead, scalp, neck, jawline and pretibial surface) are 
appropriate for MMS except focal in situ SCCs with actinic keratosis and superficial BCC with 
less than 0.5 cm diameter located in the “m-zone.” In the “L-zone” (trunk and extremities), only 
aggressive, recurrent or large tumors meeting certain criteria are considered suitable for MMS.
2.1. Basal cell carcinomas (BCC)
Recurrent BCC have been shown to have subclinical extension which might not be possible 
to identify during conventional excision. MMS has been reported to achieve better cure rates 
with these cases. It has been reported by Hoorens et al. that tumor with an area more than 
1 cm2, aggressive histology and patient age more than 80 are strong indications of MMS for 
BCC [6]. This aggressive biological behavior is characterized by sclerodermiform, infiltra-
tive, micronodular or basosquamous histology. MMS technique for these tumors can achieve 
higher cure rates when compared to standard excision [7].
2.2. Squamous cell carcinoma (SCC)
MMS can achieve better cure rates for SCC when compared to conventional surgery. Lower 
recurrence rates have been reported in SCC cases over 5-year follow-up periods with 
MMS. MMS has been shown to provide better margin control in cases with larger than 2 cm 
diameter, poor differentiation and perineural invasion in which tumors are frequently known 
to extend beyond their macroscopic margins. [8].
2.3. Melanoma in situ and lentigo maligna
The role MMS in the management of invasive melanoma is controversial since it is difficult to 
identify the atypical melanocytes in frozen section. On the other hand, successful treatment of 
melanoma in situ (MIS) has been reported with MMS. The current standard in the MIS is wide 
local excision (WLE) with 0.5–1 cm margin. In a recent study by Nosrati et al., 277 patients 
treated with MMS and 385 patients treated with WLE were compared. No significant differ-
ence between the recurrence rate and melanoma-specific survival of the patients was found. 
This study is especially valuable since prior studies did not involve any direct comparison of 
these techniques [9]. The comparison of cosmetic and functional results of MMS compared to 
WLE is still not clearly understood. Further studies are needed in this regard.
Lentigo maligna (LM) is considered as a type of melanoma in situ. MMS that has been reported 
achieves similar cure rates compared to WLE in LM cases [10].
2.4. Other tumors
Dermatofibrosarcoma protuberans (DFSP): The very high risk of recurrence associated with wide 
local excision has encouraged the use of MMS with DFSP. In spite of the absence of randomized 
controlled studies to compare MMS with WLE in DFSP, low recurrence rates associated with 
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MMS have been reported [11]. MMS can identify the subclinical extension of the tumor much 
better than the conventional WLE. It has been reported in a study that DFSP requires the highest 
number of Mohs stages when compared to other rare cutaneous tumors treated with MMS [12].
Eccrine porocarcinoma (EPC): There are no large studies comparing WLE with MMS in 
EPC. Although it has been suggested by some authors that MMS outcomes could be better 
than WLE, many surgeons prefer to treat EPC with WLE [13–15].
Microcystic adnexal carcinoma (MAC): Recurrence rates of up to 50% have been reported with 
WLE. Recurrence rates with MMS have been reported from 0 to 22% [16]. One important aspect 
of MAC is that paraffin embedding with horizontal sectioning is usually preferred instead of 
frozen sectioning since it is easier to interpret. This process is also called “slow Mohs.”
Merkel cell carcinoma: Kline and Coldiron have reported in a recent study that the MMS results 
are at least comparable to WLE. They have reported 5% recurrence rate as opposed to 32–50% 
recurrence rate with WLE [17].
Sebaceous carcinoma: Brady and Hurst have shown that MMS has been shown to be associated 
with lower recurrence and metastatic rates when compared to WLE [18].
Angiomyxoma: Despite its benign pathological features, high recurrence rates up to 40% have 
been reported with conventional surgery. MMS has been reported to decrease the recurrence 
rate significantly. But it has been argued in a paper that the pathological features of angio-
myxoma might be hard to detect with a frozen section [19].
Lymphoepithelioma, trichilemmal carcinoma, spiradenocarcinoma, nerve sheath myxoma, 
cutaneous angiosarcoma, granular cell tumor, atypical fibroxanthoma and extramammary 
Paget’s disease are among other skin tumors which have been treated with MMS.
3. Technique and principles
Conventional MMS begins with the removal of the tumor with a small free margin usually between 
1 and 2 mm depending on the tumor location as opposed to standard excision of skin cancers, in 
which at least 5 mm of margin is preferred. The lateral borders are excised at a 45° angle to allow 
for flattening of the lateral borders of the specimen. Complete circumferential peripheral and deep 
margin assessment (CCPDMA) is performed following the excision. This technique provides the 
complete evaluation of all tumor margins as opposed to traditional margin assessment. Following 
mapping of the excised tissue lateral borders are delineated with a “mashing the pie pan” technique 
and are positioned at the same horizontal level as the deep margin (Figures 1 and 2). The purpose 
of this technique is to flatten the lateral margins at the same horizontal plane as the deep margin. 
Afterwards, tissue is embedded in OCT compound in cryostat to obtain horizontal–tangential sec-
tions from the deep margin, which also contains the lateral borders after the flattening, instead of 
conventional vertical sections. Following the staining with hematoxylin and eosin (H&E) or tolu-
idine blue, slides are interpreted under microscopy. Consecutive re-excisions are performed until 
a clear surgical margin is achieved (Figure 3). The final step of MMS involves the reconstruction 




4. Outcomes and complications
There is a considerable amount of variations in the reported cure rates for MMS among differ-
ent surgeons. Misinterpretation of the pathological slides, misoriented tissue margins, freezing 
Figure 2. Flattening of the resected tissue with relaxing incisions indicated with arrows. a. b. Relaxing incisions. c. 
Flattening of the specimen.
Figure 1. Mapping of the excised tissue.
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artifacts, poor staining, difficulty of defining atypical cells in the presence of inflammation and 
scar tissues, inadequate amount of sectioning and problems with flattening the resected tissues 
are among the reasons for less than ideal outcomes of MMS. All of these can be related to poor 
training of the physicians and the technicians. Certain pitfalls can be encountered during inter-
pretation of frozen sections. These include adnexal structures which are mistaken for BCC, sun-
damaged skin resembling lentigo maligna and pseudocarcinomatous hyperplasia mistaken for 
SCC [20, 21].
Complications such as tumor recurrence, hematoma, infection, cosmetic and functional 
deformities can be seen following MMS. Lips, nasal region and eyelids are among the most 
common sites for cosmetically poor results after MMS. Plastic surgeons should be consulted 
for reconstruction in cases where the primary closure of the defect with simple methods is 
not possible.
5. Conclusion
Mohs surgery is an important technique for the treatment of certain types of skin cancer. It is 
the modality of choice for high-risk basal cell carcinomas (BCC) and squamous cell carcino-
mas, particularly for the ones located in the facial region. This method achieves very high cure 
rates for both primary and recurrent BCC. Surgeons can usually avoid large deformities of the 
face region with application of this technique. This is an important tool that requires special 
training in the surgery and the pathology of the skin.
Figure 3. Illustration of staged surgical excisions. a. preoperative view b. excision of the first layer c. positive tumor 
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